✦ LIBER ✦

PDG14: AN ASSESSMENT OF THE COSTEFFECTIVENESS OF PIOGLITAZONE (ACTOS*NF, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK

✍ Scribed by R Jansen; JO Clausen; N Maniadakis; A Kielhorn; A Brandt

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDG6: COST-EFFECTIVENESS OF PIOGLITAZONE

✍ F Henriksson; A Brandt; L Thomander; A Kielhorn; R Jansen; N Maniadakis 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PDG11: HEALTH AND ECONOMIC OUTCOMES OF A

✍ A Brandt; K Frislid; R Jansen; N Maniadakis; A Kielhorn 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PDG3: AN ECONOMIC EVALUATION OF COMBINAT

✍ N Maniadakis; J Sacristan; J Reviriego; W Hart; R Jansen; A Kielhorn; A Brandt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

PDG1: THE OUTCOMES OF LONG-TERM TREATMEN

✍ N Maniadakis; A Kielhorn; K Heikkinen; A Brandt; R Jansen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Economic Evaluation of Pioglitazone Hydr

✍ Coyle, Douglas; Palmer, Andrew J.; Tam, Robert 📂 Article 📅 2002 🏛 Springer International Publishing AG 🌐 English ⚖ 164 KB

The assessment of cardiovascular risk in

✍ Hancu, N.; Cerghizan, Anca 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 135 KB